Arrowhead Pharmaceuticals, Inc. (ARWR) stock analysis
In our weekly check, Arrowhead Pharmaceuticals, Inc. is graded D (A to F). Of 22 checks on debt, profit, cash flow and trend: 8 pass, warnings: 2, red flags: 12.
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as ARWR.
What our checks show for ARWR
Red flags
- Debt is high against equity (19.88x). That limits room in a downturn.
- The company has an operating loss, so it does not cover the interest bill: interest is paid from cash or new debt.
- The net margin fell by 88.3 points over 5 years, to -161%: the company keeps less of each sale as profit.
- Weak EPS forecast
- Weak EPS growth
- The company is losing money: the net margin is -161%.
- Free cash flow is negative (-63% of revenue): the business spends more cash than it brings in.
- The price swings a lot: 61.4% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 98% from a peak. Would you have held through that?
- Recovering from its deepest fall took about 3.9 years.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- Beta 1.37: the stock usually moves more than the market, both up and down.
- The share count grew by 18.2% in 2 years: each shareholder owns a smaller slice.
Strengths
- The gross margin is 99.6% and has risen by 3.9 points: pricing power is holding.
- Analysts expect revenue to grow about 32% a year over the next years.
- Analysts expect the net margin to improve by 144 points from today's -161%.
- Revenue grew 23.3% a year over the last 3 years.
Next earnings report: 2027-02-04
Similar companies
CGON · BLTE · CAI · KOD · TXG · IMVT
Questions
What grade does Arrowhead Pharmaceuticals, Inc. (ARWR) have?
In our weekly check, Arrowhead Pharmaceuticals, Inc. is graded D (A to F). Of 22 checks on debt, profit, cash flow and trend: 8 pass, warnings: 2, red flags: 12. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of ARWR stock?
This week's biggest flags for Arrowhead Pharmaceuticals, Inc.: High debt, Weak interest cover, Margins falling. In total 14 of 22 checks show a warning or a red flag.
What does Arrowhead Pharmaceuticals, Inc. do?
Arrowhead Pharmaceuticals, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as ARWR.
When does Arrowhead Pharmaceuticals, Inc. report earnings next?
The next earnings report is expected on 2027-02-04. We re-run the checks every week, so the grade can change after it.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis